FY2025 Earnings Estimate for ResMed Issued By Zacks Research

ResMed Inc. ( NYSE:RMD – Free Report ) – Equities researchers at Zacks Research lifted their FY2025 earnings per share (EPS) estimates for shares of ResMed in a research report issued to clients and investors on Monday, April 14th. Zacks Research analyst R.

Department now expects that the medical equipment provider will earn $9.38 per share for the year, up from their prior forecast of $9.37.



The consensus estimate for ResMed’s current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed’s Q4 2025 earnings at $2.

43 EPS, Q1 2026 earnings at $2.33 EPS, Q2 2026 earnings at $2.42 EPS, FY2026 earnings at $9.

72 EPS, Q2 2027 earnings at $2.62 EPS and FY2027 earnings at $10.66 EPS.

ResMed ( NYSE:RMD – Get Free Report ) last released its quarterly earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, beating the consensus estimate of $2.

29 by $0.14. ResMed had a net margin of 25.

34% and a return on equity of 26.17%. Get Our Latest Stock Report on ResMed ResMed Price Performance Shares of NYSE RMD opened at $211.

79 on Tuesday. ResMed has a 1 year low of $172.19 and a 1 year high of $263.

05. The stock has a market capitalization of $31.10 billion, a P/E ratio of 25.

00, a P/E/G ratio of 1.53 and a beta of 0.75.

The company’s 50-day moving average is $224.13 and its 200 day moving average is $234.91.

The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.

29. ResMed Announces Dividend The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th were paid a dividend of $0.

53 per share. The ex-dividend date of this dividend was Thursday, February 13th. This represents a $2.

12 dividend on an annualized basis and a dividend yield of 1.00%. ResMed’s dividend payout ratio is currently 25.

03%. Insider Transactions at ResMed In other news, CEO Michael J. Farrell sold 8,009 shares of the firm’s stock in a transaction dated Friday, February 7th.

The stock was sold at an average price of $236.77, for a total value of $1,896,290.93.

Following the transaction, the chief executive officer now owns 455,472 shares of the company’s stock, valued at $107,842,105.44. This trade represents a 1.

73 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink . Also, Director Peter C.

Farrell sold 2,000 shares of the firm’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $242.11, for a total transaction of $484,220.

00. Following the sale, the director now owns 77,218 shares in the company, valued at $18,695,249.98.

The trade was a 2.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here .

Insiders have sold 49,013 shares of company stock worth $11,298,816 in the last quarter. Company insiders own 0.71% of the company’s stock.

Institutional Trading of ResMed Several institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in ResMed by 0.

9% during the 4th quarter. Vanguard Group Inc. now owns 18,173,462 shares of the medical equipment provider’s stock valued at $4,156,089,000 after buying an additional 160,590 shares in the last quarter.

Geode Capital Management LLC grew its stake in ResMed by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 3,944,084 shares of the medical equipment provider’s stock valued at $899,860,000 after acquiring an additional 85,270 shares in the last quarter.

Invesco Ltd. increased its holdings in ResMed by 32.2% in the 4th quarter.

Invesco Ltd. now owns 2,325,009 shares of the medical equipment provider’s stock valued at $531,706,000 after acquiring an additional 566,046 shares during the last quarter. Northern Trust Corp grew its position in shares of ResMed by 20.

6% during the fourth quarter. Northern Trust Corp now owns 1,702,590 shares of the medical equipment provider’s stock valued at $389,365,000 after purchasing an additional 290,664 shares in the last quarter. Finally, Charles Schwab Investment Management Inc.

increased its holdings in shares of ResMed by 3.6% in the fourth quarter. Charles Schwab Investment Management Inc.

now owns 957,020 shares of the medical equipment provider’s stock worth $218,861,000 after purchasing an additional 32,973 shares during the last quarter. Hedge funds and other institutional investors own 54.98% of the company’s stock.

About ResMed ( Get Free Report ) ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.

See Also Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter ..